In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
Matteo Santoro(University of Aberdeen), Peter Teismann, Kevin J. Tracey(Unknown), Petros Stathakos(University of Bristol), Heather L. Martin(Translational Therapeutics (United States)), Tim W. Rattay(Hertie Institute for Clinical Brain Research), Walter Maetzler(Centre Hospitalier Universitaire de Lille), Thomas Gasser(Hertie Institute for Clinical Brain Research), Gernot Riedel(University of Aberdeen), Daniela Berg(Christian-Albrechts-Universität zu Kiel), John V. Forrester(University of Aberdeen), Markus A. Hobert(University Hospital Schleswig-Holstein)
Cited by 100
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Sepsis: a roadmap for future research
|The Lancet Infectious Diseases|2015|1k